Grace Therapeutics (GRCE) Current Leases (2020 - 2023)
Grace Therapeutics (GRCE) posted Current Leases of $24000.0 for Q4 2023, down 47.83% sequentially from $46000.0 in Q3 2023, and down 67.12% YoY from $73000.0 in Q4 2022.
Grace Therapeutics (GRCE) Current Leases (2020 - 2023) Analysis & Trends
Grace Therapeutics has reported Current Leases for 4 years, with the latest figure at $24000.0 in Q4 2023.
- Quarterly Current Leases fell 67.12% year-over-year to $24000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $24000.0 (down 67.12% YoY) and the FY2023 annual result came in at $75000.0, down 27.88% from the prior year.
- Current Leases eased to $24000.0 in Q4 2023 per GRCE's latest filing, from $46000.0 in the prior quarter.
- Over five years, Current Leases peaked at $645000.0 in Q2 2022 and troughed at $22000.0 in Q4 2021.
- A 4-year average of $104687.5 and a median of $75500.0 in 2020 frame the typical range for Current Leases.
- The sharpest annual moves came in 2022 and 2023: Current Leases soared 877.27% in 2022, then sank 87.6% in 2023.
- Over 4 years, Current Leases stood at $105000.0 in 2020, then slumped by 79.05% to $22000.0 in 2021, then surged by 231.82% to $73000.0 in 2022, then tumbled by 67.12% to $24000.0 in 2023.
- According to Business Quant data, Current Leases over the past three periods registered $24000.0, $46000.0, and $80000.0 for Q4 2023, Q3 2023, and Q2 2023 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Leases (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.82 Bn | 131.97 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 86.69 Bn | 78.70 Bn | 3.93 Bn | 720.00 Mn |
| 3 | Argenx Se | 65.23 Bn | 60.05 Bn | 1.37 Bn | - |
| 4 | Moderna | 60.16 Bn | 55.02 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 42.16 Bn | 37.07 Bn | 1.53 Bn | 21.95 Mn |
| 6 | Alnylam Pharmaceuticals | 31.86 Bn | 28.55 Bn | 992.69 Mn | 45.93 Mn |
| 7 | BioNTech SE | 28.24 Bn | 9.85 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.53 Bn | 26.37 Bn | 358.27 Mn | 6.27 Mn |
| 9 | Royalty Pharma | 27.31 Bn | 26.47 Bn | - | - |
| 10 | Grace Therapeutics | 37.72 Mn | 37.72 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | 24,000.00 |
| Sep 30, 2023 | 46,000.00 |
| Jun 30, 2023 | 80,000.00 |
| Mar 31, 2023 | 75,000.00 |
| Dec 31, 2022 | 73,000.00 |
| Sep 30, 2022 | 70,000.00 |
| Jun 30, 2022 | 645,000.00 |
| Mar 31, 2022 | 104,000.00 |
| Dec 31, 2021 | 22,000.00 |
| Sep 30, 2021 | 43,000.00 |
| Jun 30, 2021 | 66,000.00 |
| Mar 31, 2021 | 86,000.00 |
| Dec 31, 2020 | 105,000.00 |
| Sep 30, 2020 | 81,000.00 |
| Jun 30, 2020 | 79,000.00 |
| Mar 31, 2020 | 76,000.00 |